文献速递脑血管病

体弱房颤患者抗凝治疗的有效性与安全性

Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation.
PubMed 文献 · Stroke · 2022-02-03

这项回顾性队列研究基于韩国国民健康保险服务数据库,纳入2013年1月1日至2016年12月31日期间83635例年龄≥65岁、医院衰弱风险评分≥5的房颤患者。与未使用口服抗凝药相比,使用口服抗凝药与净不良临床事件、缺血性卒中和心血管死亡风险降低相关,但大出血无差异。与华法林相比,四种直接口服抗凝药均与净不良临床事件、缺血性卒中、大出血和心血管死亡风险降低相关。

要点

  • 在体弱房颤患者中,口服抗凝药使用与净不良临床事件风险降低相关(HR 0.78,95%CI 0.75-0.82)。
  • 口服抗凝药使用与大出血风险无显著差异(HR 1.02,95%CI 0.95-1.10)。
  • 与华法林相比,四种直接口服抗凝药均与净不良临床事件、缺血性卒中、大出血和心血管死亡风险降低相关。

核心结论

  • 在体弱房颤患者中,口服抗凝药治疗与良好的净临床结局相关。
  • 与华法林相比,直接口服抗凝药提供更低的卒中、出血和死亡率。

研究设计与样本

  • 这项回顾性队列研究分析了2013年1月1日至2016年12月31日期间来自韩国国民健康保险服务数据库的83635例年龄至少65岁、房颤且体弱(医院衰弱风险评分≥5)的患者。
  • 使用倾向评分加权以考虑接受口服抗凝药与否以及不同口服抗凝药方案之间的差异。

主要发现

  • 研究人群(57.1%女性;平均年龄78.5±7.2岁)中,共发生14968例净不良临床事件、3718例缺血性卒中、5536例大出血和6188例心血管死亡。
  • 与未使用口服抗凝药相比,使用口服抗凝药与净不良临床事件风险降低相关(HR 0.78,95%CI 0.75-0.82)。
  • 与未使用口服抗凝药相比,使用口服抗凝药与缺血性卒中风险降低相关(HR 0.91,95%CI 0.86-0.97)。
  • 与未使用口服抗凝药相比,使用口服抗凝药与心血管死亡风险降低相关(HR 0.52,95%CI 0.49-0.55)。
  • 与未使用口服抗凝药相比,使用口服抗凝药与大出血无差异(HR 1.02,95%CI 0.95-1.10)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frail patients with atrial fibrillation (AF) are less likely to receive anticoagulation than nonfrail patients with AF despite frailty being associated with poorer clinical outcomes including stroke. Using a population-based cohort, we sought to assess the effectiveness and safety of oral anticoagulants (OACs) in frail patients with AF. METHODS: This retrospective cohort study analyzed 83 635 patients aged at least 65 years with AF and frailty (≥5 Hospital Frailty Risk Score) between January 1, 2013 and December 31, 2016 from the Korean National Health Insurance Service database. To account for the differences between patients receiving OAC or not and across different OAC regimens, propensity score-weighting was used. Net adverse clinical event, defined as the first event of ischemic stroke, major bleeding, or cardiovascular death, was compared. In addition, each individual outcome was examined separately. RESULTS: In the study population (57.1% women; mean age, 78.5±7.2 years), a total of 14 968 net adverse clinical event, 3718 ischemic stroke, 5536 major bleeding, and 6188 cardiovascular death occurred. In comparison with no OAC use, OAC use was associated with lower risks of net adverse clinical event (hazard ratio, 0.78 [95% CI, 0.75-0.82]), ischemic stroke (hazard ratio, 0.91 [95% CI, 0.86-0.97]), and cardiovascular death (hazard ratio, 0.52 [95% CI, 0.49-0.55]), but no difference was observed for major bleeding (hazard ratio, 1.02 [95% CI, 0.95-1.10]). Compared with warfarin, all four individual direct OAC were associated with decreased risks of net adverse clinical event, ischemic stroke, major bleeding, and cardiovascular death. The associations for OAC use (compared to no OAC use) or direct OAC use (compared to warfarin) with favorable outcomes were more prominent in individuals with a higher CHA2DS2-VASc score of at least 3. CONCLUSIONS: Among frail patients with AF, OAC treatment was associated with a positive net clinical outcome. Direct OACs provided lower incidences of stroke, bleeding, and mortality, compared with warfarin.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kim D, Yang PS, Sung JH, et al. Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation. Stroke. 2022. PMID: 35109686. doi:10.1161/STROKEAHA.121.036757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。